Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.51 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538193 | 0.86 | HPGD (0.55) | HPGDPOLBHSD11B1HSD11B2MEN1 | |
| SCHEMBL4539384 | 0.84 | HPGD (0.54) | HPGDPOLBHSD11B1HSD11B2MEN1 | |
| SCHEMBL4536685 | 0.81 | POLB (0.51) | HPGDPOLBHSD11B1HSD11B2LMNA | |
| SCHEMBL4536746 | 0.80 | POLB (0.50) | HPGDPOLBHSD11B1HSD11B2LMNA | |
| SCHEMBL4530372 | 0.78 | POLB (0.48) | HPGDPOLBHSD11B1HSD11B2LMNA | |
| SCHEMBL4539612 | 0.78 | POLB (0.48) | HPGDPOLBHSD11B1HSD11B2LMNA | |
| SCHEMBL4565250 | 0.76 | POLB (0.46) | HPGDPOLBHSD11B1HSD11B2LMNA | |
| SCHEMBL2854296 | 0.75 | HPGD (0.96) | HPGDPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL14030255 | 0.74 | POLB (0.58) | HPGDPOLBHSD11B1HSD11B2MEN1 | |
| SCHEMBL14030375 | 0.74 | POLB (0.58) | HPGDPOLBHSD11B1HSD11B2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2009073460-A2 | INHIBITION OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 FOR OCULAR NEUROPROTECTION | BAUSCH & LOMB INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME LLC | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD11B2, HSD17B1 | HPGD 89/4885POLB 1961/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.